Top Tweets for #aaic26
Dementia prevalence increased over 2 decades in Mexico, Peru, and Puerto Rico, while rates remained stable in Cuba and the Dominican Republic, indicating an uneven and rising burden compared with high-income countries. #AAIC26 https://t.co/kLHqYXds1j
🧠 How could plasma p-tau217 transform the way participants are pre-screened and selected for Alzheimer’s disease clinical trials?
At #AAIC26, @Pamlukasewicz (of @LabPascoal) discusses how plasma biomarkers could reduce reliance on costly PET scans and enable recruitment from remote regions.
🎥 Watch the interview: https://t.co/g9pMYw63Kd
#Neurology #Dementia #Alzheimers #Alz
Researchers at #AAIC26 in London shared that a simple blood test can help predict future cognitive decline in people who are symptom-free.@SenKevinCramer the science is ready but the law isn’t. Please work with your colleagues to pass the ASAP Act. #ENDALZ
Check your emails for your #AAIC26 certificate if you had a poster/talk 🤩 On that note... we miss #AAIC26 and we wanna relive it by checking out recordings! Check out our awesome PIA member @BlasCouto sharing his work in English + Spanish for our multilingual team at #AAIC26 😎
🔬 Did you catch the exciting research news earlier this month? A study reported at #AAIC26 suggests a blood test may help predict future Alzheimer’s risk before memory or thinking problems begin.
Watch the study's senior author Reisa Sperling, Ph.D., break down the research.
Did you hear the news? 🔬
Data from a real-world study reported at #AAIC26 suggests a blood test for Alzheimer’s can improve the accuracy of a diagnosis among specialists and primary care physicians.
We asked the study's lead author Sebastian Palmqvist, M.D., Ph.D., to break down the science.
🥇Massive congratulations to @Roisin_McManus_ DZNE & Ríona Mc Ardle @UniofNewcastle who were joint winners in the Trasna na dTonnta poster competition at #AAIC26 🥳
🎊Sincere thanks to @AlzResearchUK for sponsoring the prize! Read more about our winners: https://t.co/am4hSWcXSS
At #AAIC26 last week, we announced PROTECT-Cog to evaluate whether combining lifestyle intervention with a metabolism-targeting drug like a GLP-1 agonist can further reduce dementia risk. That’s a $100 million commitment – in science, progress, and people.
📰 Today the Association announced the launch of the PROTECT-Cog Study to test U.S. POINTER lifestyle and GLP-1 or similar drug to cut risk of cognitive decline. Learn More: https://t.co/zI9i5igqLS
Fixel Institute experts Nicole Herndon and Dr. Bhavana Patel shared their expertise at #AAIC26 in London. Their presentation focused on multidisciplinary management of Lewy body dementia across the disease continuum. #LewyBodyDementia #AlzheimersAssociation
A week passed in London, in great spirit, at the @alzassociation International Conference (#AAIC26) 2026.
Surrounded by more than 11,000 like-minded people in the global dementia research community, the @CBR_IISc team spent the week reconnecting with long-time collaborators.
Over coffee conversations, meeting new potential partners in packed exhibit halls, we picked up conversations that kept circling back to the longstanding question in healthy brain aging research: how do we move faster for people living with the debilitating diseases and their families?
The conference highlighted that Alzheimer's disease diagnosis is moving towards blood-based biomarker analysis. Most importantly, such scientific advancements could predict the risk of cognitive impairment as early as 10 years before the symptoms appear.
We are sure that these blood-based tests along with good quality data analysis will give us more information on how to predict the cognitive decline as we age.
Between hallway catch-ups, poster sessions, and meetings, it was clear that the science keeps evolving, but the sense of shared purpose around aging brain health stays constant. A big thanks to the conference organisers for covering every facet of the field's growing body of knowledge on dementia.
We look forward to the 2027 AAIC in Chicago, U.S.
@iisckvshari | @sindurabg
@kris_sg
🔬 Did you catch last week's exciting research news? A study reported at #AAIC26 suggests an Alzheimer’s blood test may help predict future Alzheimer’s risk before memory or thinking problems begin.
Watch the study's senior author Reisa Sperling, Ph.D., break down the research.
"any issue, Jane's got a tissue." A one-woman cabaret about familial Alzheimer's, dark humour and all, reviewed by Dr Clíona Farrell after a long week at #AAIC26.
https://t.co/E4eJ0vya7D
Congratulations to all on another successful #AAIC26. Fantastic science including @MayoClinic @MayoClinicNeuro on #genetics, #genomics, novel #biomarkers and #therapies making #precisionmedicine a reality in #alzheimers and related diseases turning Discoveries-to-Cures @_EndAlz
IBC-Ab002, an investigational short-lived anti-PD-L1 antibody, was generally well tolerated in a phase 1b first-in-human trial of early #Alzheimer disease.
Results presented at #AAIC26.
https://t.co/8ExcLKAkE5
@alzassociation @AANmember
Oral #tau-targeting therapy #ceperognastat did not slow clinical progression in early symptomatic #Alzheimer's in a phase 2 trial presented at #AAIC26 and published in @JAMA_current.
https://t.co/VZmPDjDCaW
@alzassociation @AANmember
As @AlzResearchUK President, it’s been great to see so much progress announced at #AAIC26 in London this week. From improved delivery of Alzheimer’s treatments and promising new drugs, to advances in blood tests. Global collaboration is key to beating dementia. The UK must remain at the heart of this effort #ForACure.
This week, more than 13,000 of the brightest minds in dementia science came together for #AAIC26. 🔬 Together, they’re shaping the future of dementia science and clinical care.
We leave inspired and energized by the momentum driving Alzheimer’s and dementia research forward. There is hope in every discovery. 💜
Missed all the breaking news from #AAIC26? Here’s a wrap-up of the biggest stories in dementia research. 🧵
🧵#AAIC26 attendees, check out these findings from JAMA, @JAMANeuro, and @JAMANetworkOpen:
This clinicopathologic case report examined a patient with #Alzheimer disease and a p.R47H TREM2 variant who received long-term #aducanumab therapy.
Postmortem analysis revealed that brain regions with extensive #amyloid clearance, particularly in gyral crests, displayed less #tau #pathology and slower atrophy on serial #MRI compared with regions where amyloid persisted.
In contrast, regions with persistent amyloid, mostly in sulcal depths and deep cortical layers, showed typical tau burden and #neurodegeneration.
🔗 https://t.co/7bolxLXosc
Last Seen Hashtags on Sotwe
ดาราเซ็กซี่
Seen from Thailand
minichat
Seen from United States
brosis
Seen from France
ميقا_حصريات
Seen from Indonesia
johnscreekgladiators
Seen from United States
encoxada()**
Seen from Algeria
พัทยา
Seen from Thailand
live #pussyslip
Seen from United Kingdom
ควย18
Seen from Thailand
nepalisexvideos
Seen from Germany
Trends for you
Most Popular Users
Elon Musk 
@elonmusk
241M followers
Barack Obama
@barackobama
118.8M followers
Cristiano Ronaldo
@cristiano
114.5M followers
Donald J. Trump
@realdonaldtrump
111.9M followers
Narendra Modi
@narendramodi
107M followers
Rihanna
@rihanna
98.7M followers
NASA
@nasa
92.2M followers
Justin Bieber
@justinbieber
91.8M followers
KATY PERRY
@katyperry
90M followers
Taylor Swift
@taylorswift13
84M followers
Lady Gaga
@ladygaga
75.5M followers
Virat Kohli
@imvkohli
73.4M followers
Kim Kardashian
@kimkardashian
70.8M followers
YouTube
@youtube
68.7M followers
Neymar Jr
@neymarjr
66.4M followers
Bill Gates
@billgates
65.2M followers
Selena Gomez
@selenagomez
63.1M followers
The Ellen Show
@theellenshow
62.2M followers
CNN
@cnn
61.7M followers
X
@x
60.6M followers